Arcturus Therapeutics Holdings Inc.
ARCT Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS fell 147.1% and free cash flow fell 245.7%, each against the same quarter a year earlier.
Follow ARCT
Arcturus Therapeutics Holdings Inc. (ARCT) EV/Sales
As of 16 October 2026, Arcturus Therapeutics Holdings Inc. (ARCT) trades at a EV/Sales of 6.1×. Over the past ten years it has ranged from 0.0× (March 2018) to 248× (December 2020); the current reading is higher than 78% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.2× | (90.50%) |
| FY2024 | 1.6× | (56.03%) |
| FY2023 | 3.7× | 439.95% |
| FY2022 | 0.7× | (98.73%) |
| FY2021 | 53.9× | 18.81% |
| FY2020 | 45.4× | 1,158.90% |
| FY2019 | 3.6× | 199.80% |
| FY2018 | 1.2× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.6× | 67.33% |
| Mar 2026 | 1.5× | 893.96% |
| Dec 2025 | 0.2× | (95.60%) |
| Sep 2025 | 3.5× | 141.13% |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | 2.0× |
| AGEN Agenus Inc. compare | 2.1× |
| CCCC C4 Therapeutics, Inc. compare | 3.6× |
| ARCT Arcturus Therapeutics Holdings Inc. | 6.1× |
| OBIO Orchestra BioMed Holdings, Inc. compare | 8.5× |
| IRD Opus Genetics, Inc. compare | 31.5× |
| CYPH Cypherpunk Technologies Inc. compare | 311× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)